Magnetic resonance (MR) imaging protocols used in daily radiology practice and in the context of clinical trials often require contrast enhancement by means of intravenous administration of gadolinium based contrast agents (GBCAs). GBCAs
have been believed to be exceedingly safe and have been administered more
than 300 million times, with a very low frequency of acute adverse events.
In the past 2 years, concern has grown worldwide about the finding of gadolinium deposits in the brain in some patients undergoing GBCA-enhanced MR examinations, generating concerns in some patients, families, health institutions, regulatory agencies, and contrast media manufacturers